Summary of Zoetis Conference Call Company Overview - **Company**: Zoetis - **Industry**: Animal Health Key Financial Performance - **Fiscal Year 2025**: - Top line growth of **6%** on an organic operational basis - Bottom line growth of **7%** - Growth was **9%** in the first half and **6%** in the second half of the year [4][5] - **Fiscal Year 2026 Guidance**: - Expected top line growth between **3% and 5%** - Expected bottom line growth between **3% and 6%** [5][6] Market Dynamics - **Consumer Behavior**: - Weakness observed in the U.S. consumer market, particularly affecting pet care - Consumers are spending more on animal health, but this is driven by higher prices rather than volume [5][9] - **Livestock Portfolio**: - Continued strong growth in livestock, with growth rates of **6%**, **5%**, and **7%** over the past three years - Expected to grow in the mid-single digits in 2026, outpacing companion animal growth [5][6][16] Competitive Landscape - **Pet Care Market**: - Competitive dynamics have impacted growth, particularly in the second half of 2025 - Price increases have affected Gen Z and millennials, leading to reduced volume [7][9] - **International Business**: - International companion animal business has shown growth similar to the U.S. market - Significant opportunities exist in international markets, particularly in livestock [14][15] Product Segments - **Parasiticides**: - Global market size of nearly **$7 billion** - Triple combination products have gained significant market share, now accounting for **50%** of U.S. clinic patient share [25][26][28] - Trio product generated **$1 billion** in revenues in the U.S. last year [28] - **Dermatology**: - Revenues reached **$1.7 billion** in 2025, with room for further expansion - Competitive pressures and a decrease in therapeutic visits impacted growth in the second half of 2025 [42][43] Pipeline and Future Growth - **Pipeline Focus**: - Key areas include chronic kidney disease, oncology, cardiology, and obesity, representing a **$7 billion** total addressable market opportunity [53] - Ongoing R&D efforts to expand existing markets and address unmet needs in animal health [54][55] Capital Allocation Strategy - **Investment Priorities**: - Focus on investing in the business, including R&D and M&A - Share repurchase program remains a priority, with **$2.4 billion** remaining on the authorization [62][63] Conclusion - **Outlook for 2026**: - Despite headwinds, Zoetis remains optimistic about growth opportunities in both the companion and livestock segments - The company is well-positioned to leverage its product pipeline and market leadership to drive future growth [66][67]